期刊
JOURNAL OF THORACIC ONCOLOGY
卷 5, 期 6, 页码 786-789出版社
ELSEVIER SCIENCE INC
DOI: 10.1097/JTO.0b013e3181db3dd3
关键词
NFE2L2; Squamous cell carcinoma; EGFR; Tumor progression; mutation
资金
- Nagoya City University
- Japan Society for the Promotion of Science (JSPS) [19390367, 21390394, 21591820]
Introduction: Recently, the nuclear factor (erythroid derived 2)-like 2 (NFE2L2) gene mutations were identified in lung cancer. The constitutive activation of NFE2L2 in lung cancer cells promotes tumorigenicity. However, the correlation between NFE2L2 mutation status and clinicopathologic features of lung cancer has not been well characterized. Methods: We have investigated NFE2L2 gene mutation status in 263 surgically treated lung cancer cases at Nagoya City University Hospital. The NFE2L2 mutation was analyzed by direct sequencing of cDNA. Results: We detected 13 cases (5.1%) of NFE2L2 mutation in our cohort; all were male and all had a squamous histology. EGFR mutations were present in 78 patients (30.8%). The NFE2L2 mutation was exclusive with EGFR mutations. The NFE2L2 mutation tended to be more frequently found in patients with advanced stages. The patients with NFE2L2 mutation (n = 13, 8 were dead) had significantly worse prognosis than the patient with wild type NFE2L2 (n = 250, 72 were dead) (Log-rank test, p = 0.0032, Breslow-Gehan-Wilcoxon test, p = 0.0028). Conclusion: NFE2L2 mutations might play a role in tumor prognosis of squamous cell carcinoma of the lung.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据